Go Pro

Niagen Bioscience (NAGE) Competitors

Niagen Bioscience logo
$3.02 -0.03 (-0.98%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$3.04 +0.02 (+0.83%)
As of 08/14/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NAGE vs. ODD, BWMX, HNST, NATR, and YSG

Should you buy Niagen Bioscience stock or one of its competitors? Niagen Bioscience's main competitors and comparable companies include ODDITY Tech (ODD), Betterware de Mexico SAPI de C (BWMX), Honest (HNST), Nature's Sunshine Products (NATR), and Yatsen (YSG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Niagen Bioscience compare to ODDITY Tech?

Niagen Bioscience (NASDAQ:NAGE) and ODDITY Tech (NASDAQ:ODD) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Niagen Bioscience has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, ODDITY Tech has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

In the previous week, Niagen Bioscience had 3 more articles in the media than ODDITY Tech. MarketBeat recorded 5 mentions for Niagen Bioscience and 2 mentions for ODDITY Tech. ODDITY Tech's average media sentiment score of 1.20 beat Niagen Bioscience's score of -0.20 indicating that ODDITY Tech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Niagen Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ODDITY Tech
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ODDITY Tech has higher revenue and earnings than Niagen Bioscience. ODDITY Tech is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Niagen Bioscience$129.42M1.86$17.38M$0.1816.78
ODDITY Tech$809.84M0.93$110.75M$0.7916.59

Niagen Bioscience has a net margin of 12.39% compared to ODDITY Tech's net margin of 6.97%. Niagen Bioscience's return on equity of 17.95% beat ODDITY Tech's return on equity.

Company Net Margins Return on Equity Return on Assets
Niagen Bioscience12.39% 17.95% 13.17%
ODDITY Tech 6.97%15.38%4.99%

Niagen Bioscience presently has a consensus target price of $10.33, indicating a potential upside of 242.16%. ODDITY Tech has a consensus target price of $25.39, indicating a potential upside of 93.64%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than ODDITY Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
ODDITY Tech
4 Sell rating(s)
9 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.69

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 35.9% of ODDITY Tech shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Niagen Bioscience beats ODDITY Tech on 11 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Niagen Bioscience (NASDAQ:NAGE) and Betterware de Mexico SAPI de C (NYSE:BWMX) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Niagen Bioscience has a net margin of 12.39% compared to Betterware de Mexico SAPI de C's net margin of 8.35%. Betterware de Mexico SAPI de C's return on equity of 77.89% beat Niagen Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Niagen Bioscience12.39% 17.95% 13.17%
Betterware de Mexico SAPI de C 8.35%77.89%11.28%

Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Betterware de Mexico SAPI de C has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Betterware de Mexico SAPI de C has higher revenue and earnings than Niagen Bioscience. Betterware de Mexico SAPI de C is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Niagen Bioscience$129.42M1.86$17.38M$0.1816.78
Betterware de Mexico SAPI de C$744M0.82$55.37M$1.838.99

Niagen Bioscience currently has a consensus price target of $10.33, suggesting a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Betterware de Mexico SAPI de C
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 12.7% of Betterware de Mexico SAPI de C shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Betterware de Mexico SAPI de C had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 9 mentions for Betterware de Mexico SAPI de C and 5 mentions for Niagen Bioscience. Betterware de Mexico SAPI de C's average media sentiment score of 0.97 beat Niagen Bioscience's score of -0.20 indicating that Betterware de Mexico SAPI de C is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Niagen Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Betterware de Mexico SAPI de C
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Niagen Bioscience beats Betterware de Mexico SAPI de C on 10 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Honest?

Honest (NASDAQ:HNST) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Honest had 13 more articles in the media than Niagen Bioscience. MarketBeat recorded 18 mentions for Honest and 5 mentions for Niagen Bioscience. Honest's average media sentiment score of 0.89 beat Niagen Bioscience's score of -0.20 indicating that Honest is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Honest
9 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Niagen Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Niagen Bioscience has lower revenue, but higher earnings than Honest. Honest is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Honest$371.32M1.43-$15.69M-$0.11N/A
Niagen Bioscience$129.42M1.86$17.38M$0.1816.78

Niagen Bioscience has a net margin of 12.39% compared to Honest's net margin of -3.56%. Niagen Bioscience's return on equity of 17.95% beat Honest's return on equity.

Company Net Margins Return on Equity Return on Assets
Honest-3.56% 4.31% 3.33%
Niagen Bioscience 12.39%17.95%13.17%

Honest has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

45.5% of Honest shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 9.4% of Honest shares are owned by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Honest presently has a consensus target price of $4.84, indicating a potential upside of 0.00%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Honest.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Honest
2 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.22
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Niagen Bioscience beats Honest on 11 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Nature's Sunshine Products?

Niagen Bioscience (NASDAQ:NAGE) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Nature's Sunshine Products has higher revenue and earnings than Niagen Bioscience. Nature's Sunshine Products is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Niagen Bioscience$129.42M1.86$17.38M$0.1816.78
Nature's Sunshine Products$480.14M0.55$19.52M$1.0114.97

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 3.1% of Nature's Sunshine Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Nature's Sunshine Products had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 10 mentions for Nature's Sunshine Products and 5 mentions for Niagen Bioscience. Nature's Sunshine Products' average media sentiment score of 1.69 beat Niagen Bioscience's score of -0.20 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Niagen Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nature's Sunshine Products
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Niagen Bioscience presently has a consensus target price of $10.33, indicating a potential upside of 242.16%. Nature's Sunshine Products has a consensus target price of $30.50, indicating a potential upside of 101.72%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Niagen Bioscience is more favorable than Nature's Sunshine Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Nature's Sunshine Products
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Niagen Bioscience has a net margin of 12.39% compared to Nature's Sunshine Products' net margin of 3.68%. Niagen Bioscience's return on equity of 17.95% beat Nature's Sunshine Products' return on equity.

Company Net Margins Return on Equity Return on Assets
Niagen Bioscience12.39% 17.95% 13.17%
Nature's Sunshine Products 3.68%12.88%8.17%

Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, Nature's Sunshine Products has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Summary

Niagen Bioscience beats Nature's Sunshine Products on 11 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Yatsen?

Yatsen (NYSE:YSG) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Niagen Bioscience has a net margin of 12.39% compared to Yatsen's net margin of -3.04%. Niagen Bioscience's return on equity of 17.95% beat Yatsen's return on equity.

Company Net Margins Return on Equity Return on Assets
Yatsen-3.04% -4.54% -3.49%
Niagen Bioscience 12.39%17.95%13.17%

Yatsen has a beta of -1.55, suggesting that its share price is 255% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Niagen Bioscience has a consensus price target of $10.33, suggesting a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Yatsen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yatsen
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Niagen Bioscience has lower revenue, but higher earnings than Yatsen. Yatsen is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yatsen$614.62M0.52-$11.56M-$0.21N/A
Niagen Bioscience$129.42M1.86$17.38M$0.1816.78

In the previous week, Niagen Bioscience had 5 more articles in the media than Yatsen. MarketBeat recorded 5 mentions for Niagen Bioscience and 0 mentions for Yatsen. Yatsen's average media sentiment score of 0.00 beat Niagen Bioscience's score of -0.20 indicating that Yatsen is being referred to more favorably in the media.

Company Overall Sentiment
Yatsen Neutral
Niagen Bioscience Neutral

15.4% of Niagen Bioscience shares are held by institutional investors. 29.0% of Yatsen shares are held by insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Niagen Bioscience beats Yatsen on 14 of the 17 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAGE vs. The Competition

MetricNiagen BiosciencePersonal Care Products IndustryConsumer Staples SectorNASDAQ Exchange
Market Cap$242.91M$22.60B$16.13B$13.10B
Dividend YieldN/A4.29%3.20%10.45%
P/E Ratio16.7815.4613.3325.28
Price / Sales1.8612.56262,280.3791.94
Price / Cash15.0429.7357.6050.90
Price / Book2.902.805.066.24
Net Income$17.38M$1.08B$831.83M$347.60M
7 Day Performance-3.21%-0.93%0.59%1.06%
1 Month Performance-12.97%-0.42%1.48%0.81%
1 Year Performance-69.86%-13.80%13.68%20.90%

Niagen Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAGE
Niagen Bioscience
3.7387 of 5 stars
$3.02
-1.0%
$10.33
+242.2%
-68.9%$242.91M$129.42M16.78120
ODD
ODDITY Tech
3.7745 of 5 stars
$13.65
-10.3%
$25.39
+86.0%
-77.5%$785.50M$739.71M17.27342
BWMX
Betterware de Mexico SAPI de C
4.1228 of 5 stars
$16.79
-2.4%
N/A+27.3%$628.47M$744M9.202,441
HNST
Honest
2.0839 of 5 stars
$5.45
+41.6%
$4.18
-23.3%
+22.8%$598.39M$352.17MN/A190
NATR
Nature's Sunshine Products
4.2265 of 5 stars
$20.18
+0.6%
$34.50
+71.0%
-8.8%$354.76M$480.14M18.35850

Related Companies and Tools


This page (NASDAQ:NAGE) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners